来自MSN2 小时
Ataciguat's Headway in Aortic Stenosis; Baby Pacemakers; AI-ECG Tool for the ED?
The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...
New drug shows promise in reducing aortic valve surgeries
Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.
TCTMD5 天
Aortic Stenosis Slowed by SGLT2 Inhibitors in Observational Study
If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.
Science Daily1 天
New drug may reduce need for aortic valve surgeries by slowing disease progression
Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...
Medpage Today on MSN6 天
SGLT2 Inhibitors May Slow Nonsevere Aortic Stenosis Progression
For the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...
News Medical on MSN1 天
New drug ataciguat shows promise for managing aortic valve stenosis
Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.
Experts publish consensus on alternative access for transaortic valve replacement
The Society for Cardiovascular Angiography & Interventions (SCAI) has published an expert consensus statement that provides ...
Daily4 天
SGLT2 Inhibitors exhibit Potential for Slowing Aortic Stenosis Progression: Study
Researchers have found in a new study that SGLT2 inhibitors may have disease-modifying effects in nonsevere aortic stenosis ...
TheBetterIndia11 天
Why Women’s Hearts Deserve Better—and How Science Is Finally Catching Up
Women are often underdiagnosed and undertreated when it comes to heart disease, particularly conditions like aortic stenosis.